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doi:10.1016/j.jmii.2011.09.026Background and purpose: Carbapenem-resistant Klebsiella pneumoniae is an emerging
problem worldwide. The object of this study was to investigate the risk factors, characteristics
and outcomes of ertapenem-nonsusceptible K pneumoniae (ENSKp) bacteremia.
Methods: We conducted a 1:2 ratio matched case-control study. The controls were randomly
selected among patients with ertapenem-susceptible K pneumoniae (ESKp) bacteremia and
were matched with ENSKp cases for bacteremia.
Results: Seventy-five patients were included in this study (25 cases and 50 controls). Bivariate
analysis showed that prior exposure to either b-Lactam/b-Lactam-lactamase inhibitors
(p Z 0.008) or 4th generation cephalosporins (p < 0.001), chronic obstructive pulmonary
disease (COPD) (p Z 0.001), acute renal failure (p Z 0.021), chronic kidney disease without
dialysis (p Z 0.021), recent hospital stay (p Z 0.016), intensive care unit stay (p Z 0.002),
mechanical ventilation (p Z 0.003), central venous catheter placement (p Z 0.016), Foley
indwelling (p Z 0.022), polymicrobial bacteremia (p Z 0.003) and higher Pittsburgh bacter-
emia score (p < 0.001) were associated with ENSKp bacteremia. The multivariate analysis
showed that prior exposure to 4th generation cephalosporins (odds ratio [OR], 28.05; 95% confi-
dence interval [CI], 2.92e269.85; p Z 0.004), COPD (OR, 21.38; 95% CI, 2.95e154.92;
p Z 0.002) and higher Pittsburgh bacteremia score (OR, 1.35; 95% CI, 1.10e1.66;fectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street,
com (M.-H. Lee).
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114 S.-W. Liu et al.p Z 0.004) were independent factors for ENSKp bacteremia. ENSKp bacteremia had a higher
14-day mortality rate than ESKp bacteremia (44.0% vs. 22.0%; p Z 0.049). The overall in-
hospital mortality rates for these two groups were 60.0% and 40.0% respectively (p Z 0.102).
Conclusion: ENSKp bacteremia had a poor outcome and the risk factors were prior exposure of
4th generation cephalosporins, COPD and higher Pittsburgh bacteremia score. Antibiotic stew-
ardship may be the solution for the preventive strategy.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Klebsiella pneumoniae has caused worldwide concern
because of its ability to produce extended-spectrum b-
lactamases (ESBLs). Carbapenems have been the choice for
the management of infections caused by ESBL-producing K
pneumoniae.1 Carbapenem resistance in K pneumoniae was
first reported a decade ago2 and have emerged in several
countries subsequently.3,4
The production of carbapenem resistance in K pneumo-
niae is attributed to several mechanisms, including high-
level production of an AmpC b-lactamase combined with
loss of outer membrane proteins or, rarely, efficient
carbapenem-hydrolyzing b-lactamases (e.g., the metallo-b-
lactamases in class B by the Ambler classification).5
However, a plasmid-mediated class A carbapenem-hydro-
lyzingb-lactamase, K pneumoniae carbapenemase (KPC)
type-1, was first described in 2001 in an isolate of K pneu-
moniae from a hospital in North Carolina, USA.6 Subse-
quently, the novel enzyme family, KPC, was generally
described in the USA and has caused outbreaks since
2003, primarily in New York.5,7e9 An outbreak of bacter-
emia due to a strain of carbapenem-resistant K pneumoniae
(CRKp) was reported in Israeli hospitals in recent
years.10e12 The emergence of a new antibiotic resistance
mechanism by New Delhi metallo-b-lactamase-1 in India,
Pakistan, and the United Kingdom in 2010 has caused
worldwide concern.13
The emergence and spread of carbapenem-
nonsusceptible (intermediately resistant or resistant) K
pneumoniae is becoming a major global health problem and
a clinical challenge for physicians.14 Although risk factors
for CRKp infection have been reported by several inves-
tigators,12,15e19 there were limited observations that
focused on bloodstream infection, which may lead to
a higher mortality rate and poor outcome. Therefore, we
performed a matched case-control study to investigate
potential risk factors for the development of ertapenem-
nonsusceptible K pneumoniae (ENSKp) bacteremia and the
associated clinical outcomes.Materials and methods
Study design and patients
We conducted this study at the Chang-Gung Memorial
Hospital, Linkou Medical Center, a 3715-bed tertiary-care
general hospital in Northern Taiwan. We reviewed theblood culture records at the microbiology laboratory data-
bases to identify the bacteremia caused by ENSKp between
January 2007 and December 2009. The medical records
of patients with ENSKp bacteremia were reviewed. The
clinical characteristics of these patients was obtained,
including age, gender, dates of hospital admission, dates of
blood cultures and dates of mortality or discharge. For
patients with more than one episode of bloodstream
infection of K pneumoniae, only data relevant to the first
episode were collected and analyzed. Various risk factors
were taken into the analysis only if they had occurred
before the development of the infection. Variables analyzed
as risk factors are summarized in Table 1, including:
comorbidities; recent hospitalization (& 14 days, including
nursing home or outside hospital transferring) and surgery
(during this admission and before the bacteremia); intensive
care unit (ICU) stay; mechanical ventilation usage; place-
ment of a central venous catheter; Foley indwelling;
existence of tracheotomy, colostomy or gastrostomy;
implantation of prosthesis; polymicrobial pathogens isolated
with K pneumoniae from blood concurrently; the Pittsburgh
bacteremia score for disease severity;20 and previous
exposure to various antimicrobials. Exposure to a specific
antimicrobial agent was considered significant and included
in our analysis only if: (1) the antibiotic had been adminis-
tered for at least 3 consecutive days; and (2) that exposure
had occurred within 30 days before the development of
bacteremia.
Selection of controls
For each patient with ENSKp bacteremia, we randomly
selected two matched control patients with ertapenem-
susceptible K pneumoniae (ESKp) bacteremia from the
database. We used a stepwise matching method to identify
the appropriate control patients matched to a case for
the same gender, age 8 years, the same year of hospital
admission and length of hospital stay up to isolation of
K pneumoniae 5 days.
Microbiologic analysis
Blood cultures were processed in the clinical microbiology
laboratory, using the automated blood culture system
(BACTEC 9240 system; Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD, USA). The isolated organisms
that grew on the culture were identified according to
routine bacteriological procedures. Antibiotic susceptibility
testing was determined by the disk diffusion method in
Table 1 Clinical characteristics of 75 patients with bacteremia caused by Klebsiella pneumoniae with and without the
ertapenem-nonsusceptible phenotype
Characteristics Ertapenem-nonsusceptible
group (n Z 25)
Ertapenem-susceptible
group (n Z 50)
p
Mean  SD or No. (%) Mean  SD or No. (%)
Demographic
Gender (Male) 16 (64.0%) 32 (64.0%) 1.000
Age 64.9  16.0 (19e89) 64.9  15.4 (14e90) 0.998
Length of hospital stay (d) 46.8  26.2 (4e93) 54.4  41.8 (8e219) 0.411
Duration before bacteremia (d) 27.7  23.2 (0e76) 27.3  22.6 (0e81) 0.946
Comorbidities
Heart diseasesa 6 (24.0%) 10 (20.0%) 0.690
Malignancies (including hematologic malignancy) 9 (36.0%) 28 (56.0%) 0.102
COPD 8 (32.0%) 2 (4.0%) 0.001*
Acute renal failure 12 (48.0%) 11 (22.0%) 0.021*
Chronic kidney disease without H/D 7 (28.0%) 4 (8.0%) 0.021*
Uremia with regular dialysis 1 (4.0%) 4 (8.0%) 0.513
Diabetes mellitus 9 (36.0%) 19 (38.0%) 0.866
Chronic liver diseasesb 6 (24.0%) 11 (22.0%) 0.845
Neurologic diseases 10 (40.0%) 13 (26.0%) 0.215
Immunosuppressant usec 8 (32.0%) 9 (18.0%) 0.172
Previous transplantations 0 0 not available
Admission to the hospital (< 14 d) 11 (44.0%) 9 (18.0%) 0.016*
Intensive care unit stay 18 (72.0%) 17 (34.0%) 0.002*
Mechanical ventilation support 18 (72.0%) 18 (36.0%) 0.003*
Polymicrobial bacteremia 9 (36.0%) 4 (8.0%) 0.003*
Pittsburgh bacteremia score 6.00  3.39 (0e13) 2.98  2.81 (0e12) <0.001*
Invasive procedure or devices
Central venous catheters 21 (84.0%) 28 (56.0%) 0.016*
Foley indwelling 17 (68.0%) 20 (40.0%) 0.022*
Surgery during this admission 2 (8.0%) 16 (32.0%) 0.022*
Prosthesis placement 4 (16.0%) 5 (10.0%) 0.451
Colostomy/gastrostomy 1 (4.0%) 3 (6.0%) 0.716
Tracheostomy 3 (12.0%) 5 (10.0%) 0.791
Prior antibiotic exposure (S3 days within 30 days), including range and average days of antibiotics usage
b-Lactams (Penicillin/Ampicillin/
Amoxicillin/Oxacillin/Piperacillin)
3 (12.0%) 4 (8.0%) 0.575
(6-12, 9.3 days) (5e14, 7.5 days)
b-Lactam-lactamase inhibitorsd 8 (32.0%) 4 (8.0%) 0.008*
(5e15, 10.4 days) (4e12, 8.3 days)
1st & 2nd generation cephalosporins 1 (4.0%) 8 (16.0%) 0.132
(12, 12.0 day) (7e22, 11.8 days)
3rd generation cephalosporins 12 (48.0%) 17 (34.0%) 0.241
(4e22, 9.2 days) (4e23, 11.3 days)
4th generation cephalosporins 10 (40.0%) 1 (2.0%) <0.001*
(4e27, 9.3 days) (21, 21.0 day)
Aminoglycosides 2 (8.0%) 5 (10.0%) 0.779
(10e12, 11.0 days) (4e13, 7.6 days)
Fluoroquinolones 6 (24.0%) 7 (14.0%) 0.281
(4e13, 7.7 days) (6e17, 11.7 days)
Metronidazole 4 (16.0%) 9 (18.0%) 0.829
(4e15, 9.0 days) (4e15, 8.8 days)
Clindamycin 1 (4.0%) 2 (4.0%) 1.000
(8, 8.0 day) (6e19, 12.5 days)
Carbapenems 8 (32.0%) 8 (16.0%) 0.111
(3e18, 9.6 days) (7e20, 11.9 days)
(continued on next page)
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Table 1 (continued )
Characteristics Ertapenem-nonsusceptible
group (n Z 25)
Ertapenem-susceptible
group (n Z 50)
p
Mean  SD or No. (%) Mean  SD or No. (%)
Outcome
Appropriate antibiotic treatment 17 (68.0%) 47 (94.0%) 0.003*
Mortality, &14 days 11 (44.0%) 11 (22.0%) 0.049*
Mortality, &28 days 13 (52.0%) 15 (30.0%) 0.063
Mortality, overall 15 (60.0%) 20 (40.0%) 0.102
Days from culture to death, overall 11.3  12.7 (0e41) 23.8  31.1 (0e120) 0.117
Favorable (cure or improvement) 9 (36.0%) 30 (60.0%) 0.050
Unfavorable (stationary or deterioration) 16 (64.0%) 20 (40.0%)
COPD Z chronic obstructive pulmonary diseases; H/D Z hemodialysis; SD Z standard deviation.
* Z statistically significant (p < 0.05).
a Heart diseases included congestive heart failure, ischemic and valvular heart diseases.
b Chronic liver diseases included liver cirrhosis and chronic hepatitis.
c Immunosuppressant use included administration of steroids or immunosuppressant agents for non-hema-oncologic diseases.
d b-lactam-lactamase inhibitors included amoxicillin/clavulanic acid, ampicillin/sulbactam and piperacillin/tazobactam.
Table 2 Multivariate analysis of risk factors for













Pittsburgh bacteremia score 1.35 (1.10e1.66) 0.004*
Only risk factors in Table 1 with p value <0.05 were considered
for inclusion in a multivariable analysis.
A multivariable regression model was constructed by using
a stepwise selection procedure.
* Z statistically significant (p < 0.05).
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Standards Institute (CLSI).21 The antibiotic disks for Enter-
obacteriaceae included amoxicillin-clavulanic acid, piper-
acillin, piperacillin-tazobactam, cefazolin, cefuroxime,
ceftriaxone, ceftazidime, aztreonam, gentamicin, amika-
cin, ciprofloxacin and ertapenem. Quality control was
performed by testing Escherichia coli ATCC 25922, Pseu-
domonas aeruginosa ATCC 27853, K pneumoniae ATCC
700603 and E coli ATCC 35218. Interpretations of disk
diffusion results were made by using CLSI document M100-
S19.22 The susceptibility of K pneumoniae was initially
screened with ertapenem disk diffusion testing at the
suggestion of CLSI document M100-S19, and was confirmed
by imipenem disk diffusion, according to established
methods and breakpoints,22 and by the Etest methods with
ertapenem and imipenem, according to the manufacturer’s
instructions (AB Biodisk, Solna, Sweden).
Definition of appropriateness of antibiotic therapy
and outcomes
Appropriate antibiotic therapy was defined as the antibi-
otics being used for bacteremia were effective in vitro
against the offending pathogens and had been administered
for at least 3 days. The primary outcomes were defined as
14-day mortality, 28-day mortality and overall in-hospital
mortality. Secondary outcome was the outcome of the
infection and was assessed as either favorable (cure or
improvement) or unfavorable (stationary or deterioration).
Statistical methods
Descriptive statistics including mean, standard deviation
and range were used to summarize the continuous variables.
Descriptive statistics including the number of observations
and percentage were used to summarize the categorical
variables. For the continuous variables, an independent-t
test or ManneWhitney U test was considered for the test
statistics, depending on the validity of the normality
assumption. A Chi-square test or Fisher’s exact test wasused to test the categorical variables. Multivariate analysis
was performed using logistic regression to identify factors
that independently and significantly affected outcome.
Variables with a p value <0.05 in bivariate analyses were
considered for inclusion in a multivariate model. All statis-
tical analyses were performed using standard programs of
Statistical Package for the Social Sciences for Windows,
version 18.0 (PASW, Chicago, IL, USA).
Results
Study population
From January 2007 to December 2009, there were 1512
patients with K pneumoniae bacteremia at our hospital, and
34 of them (2.25%) had ENSKp bacteremia. The prevalence
rate increased from 1.72% in 2007 to 2.41% in 2009. By using
stepwise matching variables, including gender, age, year of
bloodstreampathogen isolation and length of hospital stay up
to isolation of K pneumonia from blood, 9 ENSKp bacteremia
patients were excluded because therewere no fully matched
Ertapenem-nonsusceptible K pneumoniae bacteremia 117patients with ESKp bacteremia for them. Therefore, 75
patients were included in this study (25 cases with ENSKp
bacteremia and 50 controls with ESKp bacteremia). TheTable 3 The analysis of the disc diffusion tests and Etests






ETP IMP ETP MIC IMP MIC
1 K pneumoniae-ESBL
strain
I S R Z 8 S Z 1
2 K Pneumoniae I S R Z 8 S Z 0.25
3 K pneumoniae-ESBL
strain
R R R > 32 R > 32
4 K Pneumoniae I I R > 32 R > 32
5 K pneumoniae-ESBL
strain
R S R Z 32 S Z 4
6 K pneumoniae-ESBL
strain
R S R > 32 S Z 1
7 K Pneumoniae R S R Z 32 S Z 0.5
8 K pneumoniae-ESBL
strain
I S R Z 16 S Z 1
9 K Pneumoniae R S R > 32 S Z 4
10 K Pneumoniae R S R > 32 S Z 4
11 K pneumoniae-ESBL
strain
R S R Z 8 S Z 4
12 K pneumoniae-ESBL
strain
R S R Z 32 S Z 0.25
13 K pneumoniae I S R Z 16 S Z 4
14 K pneumoniae R S R Z 8 S Z 2
15 K pneumoniae-ESBL
strain
R S R > 32 S Z 4
16 K pneumoniae-ESBL
strain
R S R Z 16 S Z 1
17 K pneumoniae R S R > 32 S Z 4
18 K pneumoniae I S R > 32 I Z 8
19 K pneumoniae-ESBL
strain
I S R Z 8 S Z 1
20 K pneumoniae-ESBL
strain
I S I Z 4 S Z 0.5
21 K pneumoniae-ESBL
strain
R S R > 32 S Z 1
22 K pneumoniae-MDR
strain
R R R > 32 R > 32
23 K pneumoniae-ESBL
strain
R S R > 32 I Z 8
24 K pneumoniae-MDR
strain
R I R > 32 R > 32
25 K pneumoniae-ESBL
strain
R S R > 32 S Z 2
E ESBL Z extended-spectrum-b-lactamase; ETP: ertapenem;
IMP: imipenem; I: intermediately resistant; MDR Z multidrug
resistant; MIC: minimum inhibitory concentration; R: resistant;
S: susceptible.
K pneumoniae: 9 isolates; K pneumoniae-ESBL strain: 14
isolates, K pneumoniae-MDR strain: 2 isolates.
2009 Clinical and Laboratory Standards Institute criteria for
MIC: ETP: S: &2, I Z 4, R: S8; IPM: S: &4, I Z 8, R: S16.blood isolates, disc diffusion test and Etest results of the 25
patients with ENSKp bacteremia are shown in Table 3.
Source of bacteremia
The sources of bacteremia were determined by the medical
records, image studies, surgical findings and microbiology
evidence. The definite source was defined as a culture-
proven infection site with the same organism as the blood
culture isolate. The possible infection source was defined
as a bacteremia plus a clinically suspected infection site
without culture proof. In the ENSKp bacteremia group,
pneumonia was the most common source (10 patients, 7
definite and 3 possible), and the other sources were as
follows: urinary tract infection (4, all definite), catheter-
related infection (4, 1 definite and 3 possible), liver abscess
with peritonitis (1, definite) and unidentified source (6).
Risk factors
In Table 1, we present the results of the bivariate analysis
of matched data regarding risk factors associated with
ENSKp bacteremia. Compared with the ESKp group, the
ENSKp bacteremia was more frequently seen in patients
with a history of chronic obstructive pulmonary disease
(COPD) (p Z 0.001), acute renal failure (p Z 0.021),
chronic kidney disease without dialysis (pZ 0.021), recent
access to health care facilities (i.e., nursing home or
hospital) (p Z 0.016), ICU stay (p Z 0.002), mechanical
ventilation (p Z 0.003), the placement of central venous
catheters (p Z 0.016), Foley indwelling (p Z 0.022),
simultaneous polymicrobial bacteremia with K. pneumo-
niae isolated from blood (p Z 0.003), prior exposure to b-
Lactam/b-Lactam-lactamase inhibitors (p Z 0.008) and 4th
generation cephalosporins (p < 0.001). Surgery during
hospitalization was more often seen in patients with ESKp
bacteremia (8.0% vs. 32.0%, p Z 0.022). In addition,
a higher disease severity, as indicated by a Pittsburgh
bacteremia score, was also observed in patients with ENSKp
bacteremia (6.00  3.39 vs. 2.98  2.81, p < 0.001).
We applied multivariate analysis to variables that were
statistically significant in bivariate analysis. Using a logistic
regression model, the multivariate analysis showed that
prior exposure to 4th generation cephalosporins (odds ratio
[OR], 28.05; 95% confidence interval [CI], 2.92e269.85;
p Z 0.004), history of COPD (OR, 21.38; 95% CI,
2.95e154.92; p Z 0.002) and higher Pittsburgh bacteremia
score (OR, 1.35; 95% CI, 1.10-e.66; p Z 0.004) were inde-
pendent factors for the development of ENSKp bacteremia
(Table 2).
Outcomes
Compared with the control group, patients with ENSKp
bacteremia had a higher overall mortality rate (15/25,
60.0% vs. 20/50, 40.0%, p Z 0.102). Furthermore, the case
group had a higher rate of 14-day mortality than the control
groups (11/25, 44.0% vs. 11/50, 22.0%; p Z 0.049) (Table
1). Unfavorable outcomes were more frequently found in
the ENSKp group (64.0% vs. 40.0%), even though there were
borderline statistically significant differences (p Z 0.050).
118 S.-W. Liu et al.Seventeen patients with ENSKp bacteremia received
appropriate antibiotic treatment, whereas eight received
inappropriate antibiotic treatment. Eleven of the 17
patients with ENSKp bacteremia (64.7%) who received
appropriate antibiotic treatment died, whereas four of the
eight patients (50.0%) who received inappropriate antibi-
otics died (p Z 0.484).Discussion
The emergence of CRKp in recent years and its various
resistance mechanisms5,6,13 have caused global concern
because of the threat of the spread of CRKp and limited
antibiotics choices. Many studies12,15e18 investigated the
risk factors for CRKp infection but conducted different
control groups and few focused on bacteremia, which was
a great challenge for physicians.
Our study showed that prior exposure to 4th generation
cephalosporins was an independent factor for ENSKp
bacteremia and the mean days of its usage were 9.3 days in
the case group (4w27 days) (Table 1). Two earlier studies
reported that prior exposure to cephalosporins and carba-
penems were associated with CRKp infections.15,17
However, cephalosporins had not been further subdivided
for analysis. In another study,19 prior extended-spectrum
cephalosporin use was reported as an independent risk
factor but the authors did not mention the association of 3rd
or 4th generation cephalosporins. Prior exposure to fluo-
roquinolones, antipseudomonal penicillins or carbapenems
was reported as independent risk factor of CRKp infections
by several investigators12,16,18 but this was not seen in our
study.
COPD was another independent factor for ENSKp
bacteremia in our study. A matched case-control study by
Falagas et al, which focused not only on bacteremia but
also on other sites of infection, reported that COPD was
associated with CRKp infections in bivariate analysis.16
Frequent pulmonary infections, repeated hospitalization
and multiple courses of antibiotic use were common in
patients with COPD.23 As we look to the COPD patients in
our study, pneumonia as the source of bacteremia was
noted in four of eight patients in the case group but not in
the two patients in the matched controls.
Bivariate analysis in this study revealed that poly-
microbial bacteremia was more frequently seen in the case
group than in the controls (36.0% vs. 8.0%). The concurrent
blood isolates in the case group included methicillin-
resistant Staphylococcus aureus, ESBL-producing E coli,
Pseudomonas aeruginosa, Pseudomonas cepacia, Acineto-
bacter baumannii, Stenotrophomonas maltophilia, and
glucose-nonfermenting Gram-negative bacilli, which mostly
were nosocomial pathogens.
The strikingly crude and attributable mortality rates
associated with CRKp bacteremia have been reported
before24 but the control was defined as patients who were
very similar to case subjects except that they did not have
bacteremia. In this study the case group had a statistically
significant higher rate of 14-day mortality than the
controls. This might be attributed to ENSKp bacteremia and
a lower percentage of appropriate antibiotic treatment in
the case group (68.0% vs. 94.0%). Both of the 28-daymortality and overall in-hospital mortality rates were
higher in the case group but there were no statistically
significant difference between both groups (p Z 0.063 and
pZ 0.102, respectively), which may be partially influenced
by other factors such as disease severity or underlying
diseases.
There were several limitations to our study. First, the
number of patients included in our study is relatively small,
although ertapenem resistance in K pneumoniae is rare.25
Second, we focused on bacteremia and only included
73.5% (25/34) ENSKp bacteremia patients, who had fully
matched controls using stepwise matching variables.
Furthermore, molecular epidemiology investigation for
ertapenem-resistant mechanisms among these K pneumo-
niae blood isolates was not performed although different
resistant mechanisms may influence treatment outcomes.16
In conclusion, this study provided our experience for
risk factors of the acquisition of ENSKp bacteremia and
the associated clinical outcomes. ENSKp bacteremia had
a higher 14-day mortality rate and a poor outcome, and was
associated with prior exposure to 4th generation cephalo-
sporins, COPD and higher Pittsburgh bacteremia score.
Antibiotic stewardship may be the solution for a preventive
strategy.Acknowledgments
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